Clinical Trials Logo

Cognitive Function clinical trials

View clinical trials related to Cognitive Function.

Filter by:

NCT ID: NCT04431843 Completed - Cognitive Function Clinical Trials

the Efficacy and Safety of Spirulina Maxima Extract on Improvement of Cognitive Function

Start date: March 17, 2020
Phase: N/A
Study type: Interventional

This study was the evaluate the efficacy and safety of Spirulina maxima extract on the improvement of Cognitive Function

NCT ID: NCT04430465 Completed - Overweight Clinical Trials

Effects of Wholegrains on Children's Health (KORN)

Start date: September 3, 2020
Phase: N/A
Study type: Interventional

KORN investigates the effects of wholegrain oat and rye intake on health and cognitive wellbeing in children with overweight.

NCT ID: NCT04404621 Completed - Cognitive Function Clinical Trials

Computer Presented and Physical Exercises to Maintain Cognitive Function and Emotional Health in Older Adults

Start date: November 13, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to investigate and compare how 18-weeks of computer-based brain training and physical exercise together can improve physical performance, cognitive function and mood in older adults in a cross-over design with participants randomized to receive the intervention first and then be assessed before and after an 18 week period without intervention, or the reverse sequence.

NCT ID: NCT04389723 Completed - Healthy Clinical Trials

Safety and Efficacy Study of Qualia Mind on Cognition in a Healthy Population

Start date: May 12, 2020
Phase: N/A
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, crossover study designed to investigate the safety and efficacy of Qualia Mind on cognition in a healthy adult population between ages of 18 and 75 years. Qualia Mind is a nootropic supplement containing a complex mixture of vitamins, minerals, amino acids, choline donors, and herbal ingredients. These components have been demonstrated to exert their cognitive effects through distinct mechanisms of action involving cholinergic, glutamatergic, and dopaminergic receptor signalling; neuroplasticity; and modulation of cell membrane structure and metabolism.

NCT ID: NCT04319081 Completed - Quality of Life Clinical Trials

Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors

MEMOGAL
Start date: March 1, 2020
Phase:
Study type: Observational

The main objective will be to evaluate the changes in the cognitive function in naive patients treated with PCSK9 inhibitors (Alirocumab and Evolocumab) by using the Montreal Cognitive Assesment questionnaire (MOCA). The secondary objectives will be: 1) To evaluate the levels of LDL-cholesterol changes from the beginning to the end of the study 2) To evaluate changes in Quality of Life among the EuroQol EQ-5D-3L questionnaire (it will also be associated to the cognitive function) 3) Assesment of direct costs in medications and outpatients consultations related with the health procedures.

NCT ID: NCT04196023 Completed - Cognitive Function Clinical Trials

Ca:Mg Ratio and Cognitive Function

Start date: December 12, 2012
Phase: N/A
Study type: Interventional

Between 2000 and 2015, mortality due to Alzheimer's disease (AD) increased by 123%. No drugs have yet been approved to stop or slow the progression of AD. A delay of five years in the expression of AD would reduce the incidence rate by half. Thus, it is critical to develop novel prevention strategies to delay the onset of this common disease. As an ancillary study conducted within a precision-based randomized trial (R01CA149633; PI, Dai & Yu]"), the investigators reduced Ca:Mg ratios to 2.3 through 3-month personalized Mg supplementation among those who consumed high Ca:Mg ratio diet, but otherwise in good general health. The investigators test the hypothesis that actively reducing the Ca:Mg ratio among those aged >65 years who consume high Ca:Mg ratio diets improves cognitive function compared to the placebo arm. The investigators further conduct molecular epidemiologic studies to understand the molecular mechanisms.

NCT ID: NCT04184388 Completed - Cognitive Function Clinical Trials

Efficacy and Safety of Hydrolysed Red Ginseng Extract on Improvement of Cognitive Function

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

This study was the evaluate the efficacy and safety of hydrolysed red ginseng extract on the improvement of Cognitive Function

NCT ID: NCT04143308 Completed - Schizophrenia Clinical Trials

The Effects of Simultaneous Training of Walking and Cognitive Tasks on Cognitive Functions of People With Schizophrenia

Start date: November 5, 2019
Phase: N/A
Study type: Interventional

The object is to develop a training system of simultaneous walking and cognitive training for improving cognitive function of people with schizophrenia. The training program, called "Simultaneous Walk And Think for Cognitive Health mobile application software"(SWATCH App), is developed by researchers. A randomized controlled trial will be carried out to test the effectiveness of the training system. Ninety participants will be randomly assigned to: simultaneous training of walking and cognitive group, the cognitive training group, and treatment as usual group. The intervention for those groups will lasts for 12 weeks, with a 12 week of followup. The measurements include the cognitive function, physical fitness, and quality of life.

NCT ID: NCT04070547 Completed - Cognitive Function Clinical Trials

The Effect of Transcutaneous Vagus Nerve Stimulation on Cognitive Function

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Cognitive health is generally considered a key component of quality of life. Current evidence indicates that a large number of individuals are at a high risk for cognitive impairment from many causes as they age. In order to preserve and enhance positive out-comes by targeted efficient preventive and therapeutic strategies it is important to understand potential mechanisms and predictors of cognitive health and impairment. Withdrawal of vagal (parasympathetic) activity has been proposed as one of the biological pathways involved in cognitive impairment. Transcutaneous vagus nerve stimulation (tVNS) has shown potential as a noninvasive and safe therapeutic treatment due to its direct influence on brain systems involved in cognition. However, the role of vagal modulation in cognitive functioning and impairment and the influence of tVNS, particularly long-term tVNS, on cognition are not yet completely understood. Here the investigators aim to investigate the effect of long-term (14days) intensive transcutaneous vagus nerve stimulation on cognitive functions in relatively healthy young-to-older adults.

NCT ID: NCT04025255 Completed - Cognitive Function Clinical Trials

The Memory and Cognitive Performance Study

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

The primary purpose of this study is to evaluate the impact of a novel, neuro-protective and neuro-restorative dietary supplement (Braini®) on standardized memory and cognitive performance parameters. The principal active ingredients in the Braini® supplement have been commercially-available since at least 2015 or have achieved FDA new dietary ingredient notification (NDIN) in 2018, with no adverse events reported to the FDA. A 28-day randomized, double-blinded, placebo-controlled dietary supplement study will be conducted with a cohort of younger and a cohort of colder adults to achieve the purpose of this study. The research team hypothesizes that Braini® will improve standardized performance scores measured by CNS Vital Signs standard memory and cognitive performance assays more effectively than placebo.